Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently suggested that investments in weight-loss drugs would be better spent simply ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Eli Lilly has reduced the prices of certain Zepbound ... In late February, the FDA delisted semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies have 60 or 90 days ...

Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...